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INTRODUCTION
	 Iron	deficiency	 (ID)	 is	 evident	 in	more	 than	 1.5	
billion	people	worldwide.	It	is	an	important	health	
issue	in	developing	countries	like	Asia,	Africa,	and	
South	America	and	a	frequent	cause	of	anemia	even	
in	Western	Europe.1,2	 In	 the	Western	world,	while	
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iron	deficiency	anemia	(IDA)	is	often	multi-factorial,	
menstruation	 is	 the	 commonest	 single	 cause.	
Reduced	dietary	 intake	of	 iron,	bleeding	 from	the	
gastrointestinal	 tract,	 mal-absorption	 (particularly	
in	 celiac	 disease),	 pregnancy	 and	 blood	 donation	
are	other	frequent	causes.3 
	 IDA	 is	associated	with	worsened	quality	of	 life,	
impaired	 physical	 and	 cognitive	 performance.4,5 
Effective	treatment	of	patients	with	IDA	is	therefore	
extremely	worthwhile.		Oral	iron	salts	are	the	most	
readily	 available	 way	 of	 replacing	 iron.	 Taken	
once	 or	 twice	 a	 day	 in	 tablet	 form,	 they	 are	 the	
first	 line	 treatment	 for	most	 indications.6	 Patients	
discontinue	 the	 use	 of	 oral	 iron	 therapy	 because	
of	 side	effects	and	 lack	of	 long-term	adherence	 to	
medication	 in	 iron	 deficiency	 anemia.7 The	 main	
purpose	of	this	study	was	to	investigate	the	factors	
affecting	medication	adherence	in	IDA.
METHODS
 This	 was	 a	 single	 center,	 cross-sectional	 study.	
Patient	 records	 were	 accessed	 from	 the	 page	
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which	was	 formed	 for	 patients	 with	 IDA	 for	 use	
of	authorized	personnel	only	in	Data	Management	
System	 of	 the	 Hospital.	 Record	 Supervision	
Committee	 of	 Baskent	 University	 Research	 and	
Training	 Center	 controlled	 data	 integrity	 for	
verification	and	reliability.	This	study	was	approved	
by	Baskent	University	 Institutional	Review	Board	
(Project	no:	KA	15/334)	and	supported	by	Baskent	
University	Research	Fund.
	 Standard	medication	use	was	defined	as	using	a	
total	 of	 200	mg	 ferrous	 sulfate	 preparations	 daily	
in	 two	 equal	 doses	 via	 per-oral	 route	 when	 the	
patient	 was	 fasting.	 A	 structured	 questionnaire	
method	 formed	 to	 test	 medication	 adherence	
in	 iron	 deficiency	 was	 used.	 The	 questionnaire	
was	 composed	 of	 questions	 evaluating	 	 	whether	
medications	were	used	regularly	and	the	physician	
informed	the	patients	about	the	duration	of	therapy.	
The	 questions	 about	 discontinuation	 of	 the	 drug	
due	to	relief	of	symptoms,	not	being	informed	about	
duration	 of	 therapy,	 gastrointestinal	 side	 effects	
(nausea,	 vomiting,	 distention,	 abdominal	 pain,	
constipation,	diarrhea),	weight	gain	were	asked	for	
assessment	of	treatment-related	side	effects	and	the	
influence	of	 side	effects	on	medication	adherence.	
The	questionnaire	forms	were	filled	out	with	face-
to-face	 interviews.	All	 interviews	were	 conducted	
by	the	same	family	physician.
	 The	 patients	 who	 did	 not	 have	 a	 definite	
diagnosis	for	IDA,	who	could	not	exactly	remember	
their	medication	use,	who	were	diagnosed	with	a	
malignant	 disease,	 severe	 gastrointestinal	 disease,	
psychiatric	disease	and	who	had	 to	use	any	other	
medications	 concurrently	were	excluded	 from	 the	
study.
Statistical analysis: SPSS	 17.0	 package	 program	
(SPSS	Inc.	Chicago,	Ilinois,	USA)	was	used	for	sta-
tistical	analysis.	Categorical	variables	were	summa-
rized	as	number	and	percent.	Fisher	Exact	test	was	
used	for	comparison	of	categorical	variables.
RESULTS
 A	 total	 of	 96	 female	 patients	with	mean	 age	 of	
30±10.1	 years	 (range	 18-53)	 who	 were	 admitted	
to	 Family	Medicine	Outpatient	Clinic	 between	 01	
January	2015	and	31	March	2015,	who	had	received	
oral	 iron	 therapy	 within	 the	 recent	 three	 years	
due	to	IDA	were	 included	in	the	study.	Out	of	96	
patients,	 39	 (40.6%)	 were	 detected	 not	 to	 use	 the	
medication	 regularly	or	during	 the	 recommended	
period.	Of	these	patients,	3	(3,1%)	stated	that	they	
were	not	informed	about	the	duration	of	treatment,	
4	(4,1%)	stated	that	they	discontinued	treatment	as	
her	symptoms	relieved,	36	(37.5%)	stated	that	iron	
medications	caused	gastrointestinal	side	effects	and	
of	them,	24	(66,6%)	stated	that	they	did	not	continue	
medications	 due	 to	 these	 side	 effects,	 36	 (37.5%)	
patients	 stated	 that	 the	medication	 caused	weight	
gain	and	of	them,	15	(41,6%)	stated	that	they	did	not	
comply	with	the	therapy	due	to	this	reason	(Table	
I	 and	 II).	 Some	 patients	 reported	 more	 than	 one	
reason	 for	discontinuation	of	 therapy.	There	were	
three	patients	in	intersection	set	of	gastrointestinal	
side	 effects	+	weight	gain,	 two	patients	not	being	
informed	 about	 duration	 of	 therapy	 +	 relieving	
symptoms,	 two	 patients	 in	 	 not	 being	 informed	
about	 duration	 of	 therapy	 +	 gastrointestinal	 side	
effects.	 A	 statistically	 significant	 relationship	
was	 found	 between	 incompliance	 to	 therapy	 and	
gastrointestinal	side	effects,	weight	gain	(p<0.05).
Table-II:	Distribution	of	patients	according	to	discontinuation	therapy	due	to	side	effects.
Side effect No. of the patients who No. of the patients who p
    continue the drug    discontinue the drug
 N:36 % N:36 %
Gastrointestinal	side	effects	 12	 33.3	 24	 66.6	 0.0001
Weight	gain	 21	 58.3	 15	 41.6	 0.0001
Table-I:	Reasons	for	discontinuation	therapy.
Reason Number (n):96 Percent (%)
Not	being	informed	about	duration	of	therapy	 3	 3.1
Relief	of	symptoms	 4	 4.1
Weight	gain	 15	 15.6
Gastrointestinal	side	effects	 24	 25.0
Gastrointestinal	side	effects	+	Weight	gain	 3	 3.1
Not	being	informed	about	duration	of	therapy	+	Relieving	symptoms	 2	 2.0
Not	being	informed	about	duration	of	therapy	+	Gastrointestinal	side	effects	 2	 2.0
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DISCUSSION
 Iron	 deficiency	 anemia	 is	 among	 the	 most	
common	cause	of	 anemia	worldwide,	particularly	
in	women.	Iron	deficiency	occurs	when	iron	losses	
exceed	 its	 intestinal	 absorption.	 This	 happens	 in	
patients	with	decreased	iron	intake,	mal-absorption	
of	 iron,	 increased	 demand	 for	 iron	 or	 through	
ongoing	iron	loss.8	Patients	with	ID	are	commonly	
prescribed	 oral	 iron	 preparations	 because	 of	
convenience	and	 low	cost.	 	Oral	 iron	salts	are	 the	
most	readily	available	way	of	replacing	iron.	Taken	
once	or	twice	a	day	in	tablet	form,	they	are	the	first	
line	treatment	for	most	indications.9	The	dose	of	oral	
iron	for	IDA	should	be	30-80mg	elemental	iron	daily,	
given	for	3-6	months,	and	for	longer	if	the	cause	of	
iron	deficiency	 is	 on-going.10	 Iron	 therapy	 is	used	
to	 replenish	 iron	 stores	 and	 restore	 hemoglobin	
concentrations	 to	 normal,	 thereby	preventing	 and	
treating	 symptoms	 arising	 from	 IDA.	While	most	
patients	 respond	well	 to	 oral	 iron	 preparations,	 a	
substantial	minority	have	side	effects	which	make	
them	adhere	poorly	to	their	treatment.
	 Long-term	 use	 of	 oral	 iron	 is	 limited	 by	 side	
effects	 including	 nausea,	 vomiting,	 constipation,	
and	 metallic	 taste;	 these	 side	 effects	 are	 frequent	
and,	 although	 not	 severe,	 are	 often	 worrisome	
to	 patients.	 Gastro-intestinal	 symptoms,	 which	
occur	 in	 up	 to	 30%	 of	 people	 taking	 oral	 iron,	
include	 nausea,	 flatulence,	 abdominal	 pain,	
constipation	and	diarrhea.	The	clinical	 impression	
that	 these	 side-effects	 are	 dose-related	 has	 not	
been	 confirmed	 in	 a	 recent	meta-analysis.9	 In	 our	
study,	 37.1%	of	 our	 participants	were	 detected	 to	
experience	gastrointestinal	side	effects	and	ratio	of	
discontinuation	of	 therapy	due	 to	 this	 reason	was	
found	 as	 21.3%.	 Although	 iron	 preparations	 are	
best	absorbed	when	the	patient	has	not	eaten,	they	
can	be	 taken	after	 food	 to	 reduce	gastro-intestinal	
side-effects.	 The	 gastro-intestinal	 side	 effects	
described	above	should	be	taken	seriously	as	even	
mild	 symptoms	 may	 reduce	 adherence	 to	 oral	
iron	 supplementation.	 There	 is	 limited	 evidence	
to	 suggest	 that	 switching	 to	 an	 alternative	 oral	
product	can	reduce	side	effects.	Despite	the	lack	of	
supportive	meta-analytic	data,	a	dose	reduction	is	
sometimes	effective	and	can	be	equally	efficacious	
in	 replenishing	 iron	 stores.9,11-13	 Modified-release	
preparations	 of	 iron	 are	 licensed	 for	 once-daily	
dosage,	but	have	no	proven	therapeutic	advantage	
over	conventional	 formulations.	Contrary	to	some	
reports,	 meta-analysis	 suggests	 that	 they	 are	 no	
better	 tolerated	 than	 standard	 formulations.9,14 
Several	new	formulations	of	oral	iron	are	the	focus	
of	 clinical	 trials	 and	 show	 promise	 in	 relation	
to	 efficacy	 and	 tolerability	 but	 they	 are	 not	 yet	
routinely	available.15,16
	 Despite	the	absence	of	literature	data	about	iron	
preparation-related	weight	gain,	patients	may	have	
worries	about	weight	gain.	 In	our	study,	38.2%	of	
the	patients	stated	that	iron	therapy	lead	to	weight	
gain	and	12.4%	were	detected	not	 to	comply	with	
therapy	for	the	same	reason.
CONCLUSION
 Medication	 adherence	 to	 oral	 iron	 therapy	
was	 found	 to	 be	 insufficient	 in	 IDA,	 one	 of	 the	
most	 common	 cause	 of	 anemia	 in	 primary	 care.	
The	 leading	 cause	 seems	 gastrointestinal	 side	
effects	 followed	 by	 worries	 about	 weight	 gain,	
inadequate	information	about	duration	of	therapy.	
Gastrointestinal	 side	 effects	 may	 be	 reduced	 by	
dose	reduction	or	taking	the	pills	after	meals.	The	
patients	who	have	worries	about	weight	gain	may	
be	 stated	 that	 they	 could	 increase	 their	 physical	
activity	after	hematologic	parameters	are	improved	
and	 they	 may	 be	 advised	 not	 to	 eat	 high	 calorie	
food.
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